Noticias de ALK-Abelló

Últimas noticias

Titulares en el idioma original de la fuente.

• 
  ALK-Abelló Pharmaceuticals Inc Announces Positive Funding Recommendation from Canada's Drug Agency for neffy® for the Emergency Treatment of Allergic Reactions (Anaphylaxis) (se abre en una pestaña nueva)

  1 oct 2026

• ALK expands strategic tablet supply partnership with Catalent (se abre en una pestaña nueva)

  30 sept 2026

• Why ALK-Abelló (CPSE:ALK B) Is Getting Attention Today (se abre en una pestaña nueva)

  23 sept 2026

• 
  ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy (se abre en una pestaña nueva)

  21 sept 2026

• ALK to present at the Morgan Stanley Global Healthcare Conference in New York (se abre en una pestaña nueva)

  11 sept 2026

• Alk-Abello AS (AKBLF) (Q2 2026) Earnings Call Highlights: Strong Tablet Sales and Raised ... (se abre en una pestaña nueva)

  20 ago 2026

• ALK appoints Jacob Glenting as head of Global R&D (se abre en una pestaña nueva)

  20 ago 2026

• Six-month interim report (Q2) 2026 (unaudited) (se abre en una pestaña nueva)

  20 ago 2026

• ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system (se abre en una pestaña nueva)

  14 ago 2026

• Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026 (se abre en una pestaña nueva)

  13 ago 2026

• Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada (se abre en una pestaña nueva)

  5 ago 2026

• Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight (se abre en una pestaña nueva)

  27 jul 2026

• Is It Too Late To Consider ALK-Abelló (CPSE:ALK B) After Strong Multi‑Year Gains? (se abre en una pestaña nueva)

  5 jun 2026

• ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026 (se abre en una pestaña nueva)

  4 jun 2026

• ALK to present at the Jefferies Global Healthcare Conference in New York (se abre en una pestaña nueva)

  29 may 2026

• Three-month interim report (Q1) 2026 (unaudited) (se abre en una pestaña nueva)

  4 may 2026

• ALK upgrades its full-year outlook (se abre en una pestaña nueva)

  4 may 2026

• Assessing ALK Abelló (CPSE:ALK B) Valuation After Strong Recent Share Price Momentum (se abre en una pestaña nueva)

  2 may 2026

• Invitation to the presentation of ALK’s first quarter 2026 results on Tuesday, 5 May 2026 (se abre en una pestaña nueva)

  28 abr 2026

• Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff (se abre en una pestaña nueva)

  8 abr 2026